Neurotrophic Keratopathy clinical trials

Explore recruiting neurotrophic keratopathy clinical trials.

Recruiting neurotrophic keratopathy studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neurotrophic Keratopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy

Italy, Spain, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Italy, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neurotrophic Keratopathy trials by city

Neurotrophic Keratopathy clinical trials

Recruiting neurotrophic keratopathy studies right now

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Also recruiting in Europe

SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Neurotrophic Keratopathy trials by city

Other conditions